Table 3.
Multivariate COX analysis of HSPG2 and MESO prognosis
| OS | DSS | PFI | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | ||||||||||
| Characteristics | Total(N) | HR(95% CI) | P value | HR(95% CI) | P value | Total(N) | HR(95% CI) | P value | HR(95% CI) | P value | Total(N) | HR(95% CI) | P value | HR(95% CI) | P value |
| Pathologic T stage | 84 | 65 | 82 | ||||||||||||
| T1 | 14 | Reference | 11 | Reference | 13 | Reference | |||||||||
| T2 | 25 |
0.977 (0.470—2.032) |
0.950 | 21 |
0.679 (0.254—1.816) |
0.440 | 25 |
0.921 (0.412—2.056) |
0.841 | ||||||
| T3 | 32 |
1.056 (0.519—2.149) |
0.880 | 22 |
0.953 (0.370—2.456) |
0.921 | 32 |
0.860 (0.394—1.881) |
0.706 | ||||||
| T4 | 13 |
0.775 (0.327—1.838) |
0.563 | 11 |
0.821 (0.283—2.382) |
0.716 | 12 |
0.611 (0.234—1.593) |
0.314 | ||||||
| Pathologic N stage | 82 | 62 | 80 | ||||||||||||
| N0 | 44 | Reference | 36 | Reference | 42 | Reference | |||||||||
| N1 | 10 |
0.919 (0.443—1.909) |
0.822 | 5 |
0.380 (0.090—1.609) |
0.189 | 10 |
0.604 (0.251—1.451) |
0.259 | ||||||
| N2 | 25 |
0.805 (0.462—1.405) |
0.446 | 19 |
0.627 (0.308—1.280) |
0.200 | 25 |
0.642 (0.347—1.190) |
0.159 | ||||||
| N3 | 3 |
1.753 (0.536—5.732) |
0.353 | 2 |
1.535 (0.358—6.577) |
0.563 | 3 |
1.768 (0.416—7.513) |
0.440 | ||||||
| Pathologic M stage | 60 | 54 | 59 | ||||||||||||
| M0 | 57 | Reference | 51 | Reference | 57 | Reference | |||||||||
| M1 | 3 |
1.856 (0.441—7.817) |
0.399 | 3 |
2.327 (0.541—10.007) |
0.257 | 2 |
1.094 (0.147—8.129) |
0.930 | ||||||
| Pathologic stage | 86 | 66 | 84 | ||||||||||||
| Stage I | 10 | Reference | 7 | Reference | 10 | Reference | |||||||||
| Stage II | 16 |
0.631 (0.265—1.507) |
0.300 | 15 |
0.297 (0.094—0.937) |
0.038 | 16 |
0.556 (0.221—1.401) |
0.213 | ||||||
| Stage III | 44 |
0.756 (0.359—1.592) |
0.461 | 31 |
0.303 (0.107—0.860) |
0.025 | 44 |
0.61 5 (0.280—1.349) |
0.225 | ||||||
| Stage IV | 16 |
0.705 (0.297—1.674) |
0.428 | 13 |
0.390 (0.127—1.199) |
0.100 | 14 |
0.448 (0.171—1.174) |
0.102 | ||||||
| Gender | 86 | 66 | 84 | ||||||||||||
| Female | 16 | Reference | 15 | Reference | 16 | Reference | Reference | ||||||||
| Male | 70 |
0.888 (0.494—1.595) |
0.691 | 51 |
0.843 (0.424—1.676) |
0.626 | 68 |
0.523 (0.285—0.961) |
0.037 |
0.395 (0.207—0.752) |
0.005 | ||||
| Age | 86 | 66 | 84 | ||||||||||||
| < = 65 | 46 | Reference | 34 | Reference | 45 | Reference | |||||||||
| > 65 | 40 |
1.325 (0.826—2.125) |
0.243 | 32 |
1.031 (0.563—1.887) |
0.922 | 39 |
1.319 (0.787—2.210) |
0.294 | ||||||
| Histological type | 86 | 66 | 84 | ||||||||||||
| Biphasic | 23 | Reference | Reference | 18 | Reference | 22 | Reference | ||||||||
| Diffuse malignant | 5 |
0.575 (0.215—1.540) |
0.271 |
0.638 (0.238—1.708) |
0.371 | 5 |
0.766 (0.270—2.172) |
0.616 | 4 |
0.834 (0.281—2.476) |
0.743 | ||||
| Epithelioid | 57 |
0.497 (0.293—0.842) |
0.009 |
0.586 (0.343—1.001) |
0.051 | 42 |
0.506 (0.256—0.998) |
0.049 | 57 |
0.496 (0.279—0.882) |
0.017 | ||||
| Sarcomatoid | 1 |
3.418 (0.438—26.654) |
0.241 |
2.718 (0.347—21.280) |
0.341 | 1 | 0.000 (0.000—Inf) | 0.997 | 1 |
0.000 (0.000—Inf) |
0.997 | ||||
| Residual tumor | 35 | 34 | 34 | ||||||||||||
| R0 | 17 | Reference | 16 | Reference | 17 | Reference | |||||||||
| R1 | 3 |
0.634 (0.144—2.798) |
0.548 | 3 |
1.501 (0.290—7.773) |
0.628 | 3 |
0.796 (0.165—3.836) |
0.777 | ||||||
| R2 | 15 |
1.223 (0.572—2.617) |
0.604 | 15 |
2.786 (0.992—7.831) |
0.052 | 14 |
2.510 (1.040—6.059) |
0.041 | ||||||
| History asbestos exposure | 69 | 51 | 68 | ||||||||||||
| No | 14 | Reference | 8 | Reference | 14 | Reference | |||||||||
| Yes | 55 |
0.988 (0.520—1.879) |
0.972 | 43 |
1.391 (0.468—4.136) |
0.553 | 54 |
1.590 (0.711—3.560) |
0.259 | ||||||
| Laterality | 86 | 66 | 84 | ||||||||||||
| Bilateral | 3 | Reference | 0 | Reference | 3 | Reference | |||||||||
| Left | 30 |
1.144 (0.344—3.799) |
0.827 | 22 |
0.687 (0.357—1.321) |
0.260 | 30 |
2.367 (0.316—17.720) |
0.402 | ||||||
| Right | 53 |
1.424 (0.441—4.606) |
0.555 | 44 | 51 |
3.539 (0.485—25.812) |
0.213 | ||||||||
| Radiation therapy | 85 | 65 | 83 | ||||||||||||
| No | 60 | Reference | 41 | Reference | 58 | Reference | |||||||||
| Yes | 25 |
0.682 (0.403—1.155) |
0.155 | 24 |
0.761 (0.409—1.417) |
0.389 | 25 |
0.805 (0.462—1.403) |
0.444 | ||||||
| HSPG2 | 86 | 66 | 84 | ||||||||||||
| Low | 43 | Reference | Reference | 36 | Reference | Reference | 43 | Reference | Reference | ||||||
| High | 43 |
2.447 (1.500—3.991) |
< 0.001 |
2.219 (1.347—3.656) |
0.002 | 30 |
3.056 (1.597—5.849) |
< 0.001 |
3.056 (1.597—5.849) |
< 0.001 | 41 |
1.835 (1.068—3.150) |
0.028 |
2.264 (1.279—4.010) |
0.005 |